Abbott Laboratories (ABT)
Healthcare · end-of-day data as of Oct 16, 2026
The average 12-month analyst price target for ABT is $122.35, 16.6% above the last close of $104.89 on Oct 16, 2026; targets range from $89.76 to $148.01. Rating consensus: Buy.
Snapshot
- P/E33.7x
- P/E vs sector+19.8%
- P/E vs own+24.7%
- Target upside+16.6%
- ConsensusBuy
- Market cap$181B
- FCF yield+4.8%
- Insiders-$46.85M
- Earnings in5d
- News
Why it moved
Abbott Laboratories (ABT) rose 0.2% on Oct 16, 2026.
The market (SPY) fell 1.1%; Healthcare stocks fell 0.7%. Most of the move came from the market as a whole.
2 stories on the day (30-day average 1.8).
- Abbott Laboratories $ABT Stock: Banque Pictet & Cie SA Increases Stake
- Countdown to Abbott (ABT) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.
Price and events
Last close $104.89 · -15.8% over 1y · E earnings · D dividend · S split · A analyst rating change
Technicals
- Trendsideways
- Sector▲ +16.0%
- MAs20▲ 50▼ 100▲ 200▲
- Above MAs3 of 4 above
- MA20×50↑ in ~43d
- RSI61
- Support-1.8%
- Resistance+3.3%
- Off 52w high-17.7%
- Off ATH-22.3%
- 52w range$104.89
- Bollingerupper half
- MACD0.97
- ATR+2.2%
- Volume0.9x
Analyst price targets
18 firms with a target in the last 12 months · last close $104.89 · as of Oct 16, 2026
Strong buy 5 · Buy 19 · Hold 5 · Sell 0 · Strong sell 0
Revenue and free cash flow
Q2 FY2026: Revenue +13.0% year over year, free cash flow 22.9% of revenue, operating margin 14.2%.
| Q2 FY2026 | Jun 30, 2026 | $12.59B | 0.53 | $2.89B | 58.0% | 14.2% | 7.4% |
| Q1 FY2026 | Mar 31, 2026 | $11.16B | 0.62 | $916M | 56.3% | 16.5% | 9.6% |
| Q4 FY2025 | Dec 31, 2025 | $11.46B | 1.02 | $2.63B | 57.0% | 19.6% | 15.5% |
| Q3 FY2025 | Sep 30, 2025 | $11.37B | 0.94 | $2.29B | 55.7% | 18.1% | 14.5% |
| Q2 FY2025 | Jun 30, 2025 | $11.14B | 1.01 | $1.54B | 56.4% | 18.4% | 16.0% |
| Q1 FY2025 | Mar 31, 2025 | $10.36B | 0.76 | $933M | 52.6% | 16.3% | 12.8% |
| Q4 FY2024 | Dec 31, 2024 | $10.97B | 5.27 | $2.15B | 51.0% | 18.1% | 84.1% |
| Q3 FY2024 | Sep 30, 2024 | $10.63B | 0.94 | $2.15B | 51.0% | 17.1% | 15.5% |
Peers
| 20D | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 | | $104.89 | +0.2% | -17.7% | +16.6% | 33.7 | $181B | |
| 2 |  | $94.75 | -0.7% | -7.1% | +4.0% | 23.3 | $121B | |
| 3 |  | $294.66 | +0.5% | -23.3% | +23.9% | 30.5 | $113B | |
| 4 |  | $44.39 | +0.6% | -57.7% | +50.1% | 18.0 | $64.33B | |
| 5 |  | $86.60 | -1.7% | -9.0% | +15.2% | 49.8 | $49.9B | |
| 6 |  | $86.04 | -1.9% | -6.8% | +12.7% | 34.0 | $32.47B | |
| 7 |  | $69.57 | -1.1% | -21.0% | +20.2% | 20.2 | $31.42B | |
| 8 |  | $94.98 | +0.6% | -7.7% | +9.0% | 23.1 | $18.12B |
Data as of Oct 16, 2026 close.
Latest news
Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.